Skip to main content
SpringerLink
Log in

Anti-D: A Type of IVIg

  • Chapter
  • First Online:
Antibody Therapy

Abstract

Anti-D is a polyclonal IgG antibody isolated from donor-derived IVIg. It is directed against the D antigen present on human red blood cells and is clinically used to treat immune thrombocytopenia and to prevent the hemolytic disease of the fetus and newborn. As a donor-derived product, anti-D is available in limited quantities and carries a theoretical risk of potentially transferring emerging pathogens. Over the years, research performed in clinical studies and using murine models has proposed multiple mechanisms of action including mononuclear phagocytic system blockage, cytokine modulation, and the presence of idiotypic antibodies. Although a wealth of information has been generated, more research will help to fully elucidate the mechanism of action of anti-D, which can then be applied to develop a recombinant replacement for clinical use.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Ambriz-Fernández R, Martínez-Murillo C, Quintana-González S, Collazo-Jaloma J, Bautista-Juárez J. Fc receptor blockade in patients with refractory chronic immune thrombocytopenic purpura with anti-D IgG. Arch Med Res. 2002;33:536–40.

    Article  PubMed  Google Scholar 

  • Becker T, Küenzlen E, Salama A, Mertens R, Kiefel V, Weiss H, Lampert F, Gaedicke G, Mueller-Eckhardt C. Treatment of childhood idiopathic thrombocytopenic purpura with rhesus antibodies (anti-D). Eur J Pediatr. 1986;145:166–9.

    Article  CAS  PubMed  Google Scholar 

  • Boughton B. Anti-D Ig for treatment of immune thrombocytopenic purpura [letter; comment]. Blood. 1991;78:2157–8.

    CAS  PubMed  Google Scholar 

  • Boughton BJ, Cooke RM, Smith NA, Simpson AW. Autoimmune thrombocytopenia: anti-glycoprotein IIb/IIIa auto antibodies are reduced after human anti-D immunoglobulin treatment. Autoimmunity. 1994;18:141–4.

    Article  CAS  PubMed  Google Scholar 

  • Branch DR, Shabani F, Lund N, Denomme GA. Antenatal administration of Rh-immune globulin causes significant increases in the immunomodulatory cytokines transforming growth factor-Beta and prostaglandin E2. Transfusion. 2006;46:1316–22.

    Article  CAS  PubMed  Google Scholar 

  • Brinc D, Lazarus AH. Mechanisms of anti-D action in the prevention of hemolytic disease of the fetus and newborn. Hematology Am Soc Hematol Educ Program. 2009;2009(1):185–91.

    Google Scholar 

  • Bruhns P, Jönsson F. Mouse and human FcR effector functions. Immunol Rev. 2015;268:25–51.

    Article  CAS  PubMed  Google Scholar 

  • Bussel J, Graziano J, Kimberly R, Pahwa S, Aledort L. Intravenous anti-D treatment of immune thrombocytopenic purpura: analysis of efficacy, toxicity, and mechanism of effect [see comments]. Blood. 1991;77:1884–93.

    CAS  PubMed  Google Scholar 

  • Chen X, Ghaffar H, Jen CC, Lazarus AH. Antibody specific for the glycophorin A complex mediates intravenous immune globulin-resistant anemia in a murine model. Transfusion. 2014;54:655–64.

    Article  CAS  PubMed  Google Scholar 

  • Coopamah MD, Freedman J, Semple JW. Anti-D initially stimulates an Fc-dependent leukocyte oxidative burst and subsequently suppresses erythrophagocytosis via interleukin-1 receptor antagonist. Blood. 2003;102:2862–7.

    Article  CAS  PubMed  Google Scholar 

  • Cooper N, Heddle NM, Haas M, Reid ME, Lesser ML, Fleit HB, Woloski BM, Bussel JB. Intravenous (IV) anti-D and IV immunoglobulin achieve acute platelet increases by different mechanisms: modulation of cytokine and platelet responses to IV anti-D by FcgammaRIIa and FcgammaRIIIa polymorphisms. Br J Haematol. 2004;124:511–8.

    Article  CAS  PubMed  Google Scholar 

  • Crow AR, Songs S, Semple JW, Freedman J, Lazarus AH. A role for IL-1 receptor antagonist or other cytokines in the acute therapevtic effects of ivlg?. Blood. 2007;22:109:155–8.

    Google Scholar 

  • Crow AR, Lazarus AH. The mechanisms of action of intravenous immunoglobulin and polyclonal anti-D immunoglobulin in the amelioration of immune thrombocytopenic purpura: what do we really know? Transfus Med Rev. 2008;22:103–16.

    Article  PubMed  Google Scholar 

  • Davenport RD, Burdick MD, Strieter RM, Kunkel SL. In vitro production of Interleukin-1 receptor antagonist in IgG-mediated red cell incompatibility. Transfusion. 1994;34:297–303.

    Article  CAS  PubMed  Google Scholar 

  • Deng R, Balthasar JP. Comparison of the effects of antibody-coated liposomes, IVIG, and anti-RBC immunotherapy in a murine model of passive chronic immune thrombocytopenia. Blood. 2007;109(6):2470.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Despotovic JM, Lambert MP, Herman JH, Gernsheimer TB, Mccrae KR, Tarantino MD, Bussel JB. RhIG for the treatment of immune thrombocytopenia: consensus and controversy (CME). Transfusion. 2012;52:1126–36; Quiz 1125.

    Article  CAS  PubMed  Google Scholar 

  • Dripps DJ, Brandhuber BJ, Thompson RC, Eisenberg SP. Interleukin-1 (IL-1) receptor antagonist binds to the 80-kDA IL-1 receptor but does not initiate IL-1 signal transduction. J Biol Chem. 1991;266:10331–6.

    CAS  PubMed  Google Scholar 

  • Eghbali A, Azadmanesh P, Bagheri B, Taherahmadi H, Sadeghi Sedeh B. Comparison between IV immune globulin (IVIG) and anti-D globulin for treatment of immune thrombocytopenia: a randomized open-label study. Fundam Clin Pharmacol. 2016;30:385–9.

    Article  CAS  PubMed  Google Scholar 

  • FDA U. Warning - Rh(D) immune globulin intravenous (Human). In: Administration, F. A. D. editor. 2009.

    Google Scholar 

  • Godeau B, Oksenhendler E, Brossard Y, Bartholeyns J, Leaute JB, Duedari N, Schaeffer A, Bierling P. Treatment of chronic autoimmune thrombocytopenic purpura with monoclonal anti-D. Transfusion. 1996;36:328–30.

    Article  CAS  PubMed  Google Scholar 

  • Hendrickson JE, Delaney M. Hemolytic disease of the fetus and newborn: modern practice and future investigations. Transfus Med Rev. 2016;30:159–64.

    Article  PubMed  Google Scholar 

  • Hume DA. The mononuclear phagocyte system. Curr Opin Immunol. 2006;18:49–53.

    Article  CAS  PubMed  Google Scholar 

  • Imbach P, Barandun S, D'apuzzo V, Baumgartner C, Hirt A, Morell A, Rossi E, Schöni M, Vest M, Wagner HP. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet. 1981;1:1228–31.

    Article  CAS  PubMed  Google Scholar 

  • Kumpel BM. Efficacy of RhD monoclonal antibodies in clinical trials as replacement therapy for prophylactic anti-D immunoglobulin: more questions than answers. Vox Sang. 2007;93:99–111.

    Article  CAS  PubMed  Google Scholar 

  • Lazarus AH. Monoclonal versus polyclonal anti-D in the treatment of ITP. Expert Opin Biol Ther. 2013;13:1353–6.

    Article  CAS  PubMed  Google Scholar 

  • Malinowska I, Obitko-Płudowska A, Buescher ES, Wasik M, Rokicka-Milewska R. Release of cytokines and soluble cytokine receptors after intravenous anti-D treatment in children with chronic thrombocytopenic purpura. Hematol J. 2001;2:242–9.

    Article  CAS  PubMed  Google Scholar 

  • Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 2016;7:27–31.

    Article  PubMed  PubMed Central  Google Scholar 

  • Oksenhendler E, Bierling P, Brossard Y, Schenmetzler C, Girard PM, Seligmann M, Clauvel JP. Anti-RH immunoglobulin therapy for human immunodeficiency virus-related immune thrombocytopenic purpura. Blood. 1988;71:1499–502.

    CAS  PubMed  Google Scholar 

  • Ramadan KM, El-Agnaf M. Efficacy and response to intravenous anti-D immunoglobulin in chronic idiopathic thrombocytopenic purpura. Clin Lab Haematol. 2005;27:267–9.

    Article  CAS  PubMed  Google Scholar 

  • Robak T, Windyga J, Trelinski J, Von Depka Prondzinski M, Giagounidis A, Doyen C, Janssens A, Alvarez-Román MT, Jarque I, Loscertales J, Rus GP, Hellmann A, Jêdrzejczak WW, Kuliczkowski K, Golubovic LM, Celeketic D, Cucuianu A, Gheorghita E, Lazaroiu M, Shpilberg O, Attias D, Karyagina E, Svetlana K, Vilchevska K, Cooper N, Talks K, Prabhu M, Sripada P, Bharadwaj TP, Næsted H, Skartved NJ, Frandsen TP, Flensburg MF, Andersen PS, Petersen J. Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia. Blood. 2012;120:3670–6.

    Article  CAS  PubMed  Google Scholar 

  • Rosman Z, Shoenfeld Y, Zandman-Goddard G. Biologic therapy for autoimmune diseases: an update. BMC Med. 2013;11:88.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Salama A, Kiefel V, Amberg R, Mueller-Eckhardt C. Treatment of autoimmune thrombocytopenic purpura with rhesus antibodies anti-Rh0(D). Blut. 1984;49:29–35.

    Article  CAS  PubMed  Google Scholar 

  • Salama A, Mueller-Eckhardt C, Kiefel V. Effect of intravenous immunoglobulin in immune thrombocytopenia. Lancet. 1983;2:193–5.

    Article  CAS  PubMed  Google Scholar 

  • Semple JW. Anti-D: basic concepts and mechanisms of action in autoimmunity. In: Lazarus AH, Semple JW, editors. Immunoglobulin therapy. Bethesda: Aabb Press; 2010.

    Google Scholar 

  • Semple JW, Allen D, Rutherford M, Woloski M, David M, Wakefield C, Butchart S, Freedman J, Blanchette V, Group, C. C. S. P. S. Anti-D (WinRho SD) treatment of children with chronic autoimmune thrombocytopenic purpura stimulates transient cytokine/chemokine production. Am J Hematol. 2002;69:225–7.

    Article  CAS  PubMed  Google Scholar 

  • Song S, Crow AR, Freedman J, Lazarus AH. Monoclonal IgG can ameliorate immune thrombocytopenia in a murine model of ITP: an alternative to IVIG. Blood. 2003;101:3708–13.

    Article  CAS  PubMed  Google Scholar 

  • Song S, Crow AR, Siragam V, Freedman J, Lazarus AH. Monoclonal antibodies that mimic the action of anti-D in the amelioration of murine ITP act by a mechanism distinct from that of IVIg. Blood. 2005;105:1546–8.

    Article  CAS  PubMed  Google Scholar 

  • Urbaniak SJ, Greiss MA. RhD haemolytic disease of the fetus and the newborn. Blood Rev. 2000;14:44–61.

    Article  CAS  PubMed  Google Scholar 

  • Ware RE, Zimmerman SA. Anti-D: mechanisms of action. Semin Hematol. 1998;35:14–22.

    CAS  PubMed  Google Scholar 

  • Yu X, Menard M, Seabright G, Crispin M, Lazarus AH. A monoclonal antibody with anti-D-like activity in murine immune thrombocytopenia requires Fc domain function for immune thrombocytopenia ameliorative effects. Transfusion. 2015;55:1501–11.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Toronto, ON, Canada

    Ramsha Khan HBSc

  2. Keenan Research Centre of the Li Ka Shing Knowledge Institute at St. Michael’s Hospital, Toronto, ON, Canada

    Ramsha Khan HBSc & Alan H. Lazarus PhD

  3. Centre for Innovation at The Canadian Blood Services, Ottawa, ON, Canada

    Alan H. Lazarus PhD

  4. Departments of Medicine and Laboratory Medicine & Pathobiology, Faculty of Medicine, University of Toronto, Toronto, ON, Canada

    Alan H. Lazarus PhD

Authors
  1. Ramsha Khan HBSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alan H. Lazarus PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alan H. Lazarus PhD .

Editor information

Editors and Affiliations

  1. Department of Pediatrics, Medical Faculty of the University of Basel, Basel, Switzerland

    Paul Imbach

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Khan, R., Lazarus, A.H. (2018). Anti-D: A Type of IVIg. In: Imbach, P. (eds) Antibody Therapy. Springer, Cham. https://doi.org/10.1007/978-3-319-68038-5_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-68038-5_5

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-68037-8

  • Online ISBN: 978-3-319-68038-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation